|
Succinylcholine
drug data and news
Succinylcholine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Succinylcholine
|
| Brand Names/Synonyms |
Anectine; Quelicin; Quelicin Preservative Free; Succinylcholine; Succinylcholine Chloride; Sucostrin |
| Indication |
Used in surgical procedures where a rapid onset and brief duration of muscle relaxation is needed (includes intubation, endoscopies, and ECT) |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Succinylcholine is a depolarizing skeletal muscle relaxant. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the receptor site. Succinylcholine has no direct action on the uterus or other smooth muscle structures. |
| Mechanism Of Action |
The mechanism of action of Succinylcholine involves what appears to be a "persistent" depolarization of the neuromuscular junction. This depolarization is caused by Succinylcholine mimicking the effect of acetylcholine but without being rapidly hydrolysed by acetylcholinesterase. This depolarization leads to desensitization. |
Succinylcholine News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
LIQUID |
| Drug_Category |
Neuromuscular Depolarizing Agents; Skeletal Muscle Relaxants; ATC:M03BX |
| Absorption |
Not Available |
| Interactions |
-->Interactions for Succinylcholine:
Drugs which may enhance the neuromuscular blocking action of succinylcholine include: promazine,
oxytocin, aprotinin, certain non-penicillin antibiotics, quinidine, b-adrenergic blockers,
procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, diethylether,
isoflurane, desflurane, metoclopramide, and terbutaline. The neuromuscular blocking effect of succinylcholine may be
enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives,
glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma
cholinesterase.
If other neuromuscular blocking agents are to be used during the same procedure, the possibility of a
synergistic or antagonistic effect should be considered.
|
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
trimethyl-[2-[3-(2-trimethylammonioethoxycarbonyl)propanoyloxy]ethyl]ammonium |
| Chemical Formula |
C14H30N2O4 |
| Molecular Weight |
290.399 g/mol |
| Smiles String |
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C |
| Melting Point |
Not Available |
| Water Solubility |
Not Available |
| State |
Solid |
| LogP/Hphobicity |
Not Available |
| Isoelectric Point |
Not A | |
